High-Sensitivity Cardiac Troponin I and B-Type Natriuretic Peptide as Predictors of Vascular Events in Primary Prevention: Impact of Statin Therapy

Citation
Everett, Brendan M., Tanja Zeller, Robert J. Glynn, Paul M Ridker, and Stefan Blankenberg. 2015. “High-Sensitivity Cardiac Troponin I and B-Type Natriuretic Peptide as Predictors of Vascular Events in Primary Prevention: Impact of Statin Therapy.” Circulation 131 (21): 1851-1860. doi:10.1161/CIRCULATIONAHA.114.014522. http://dx.doi.org/10.1161/CIRCULATIONAHA.114.014522.

Published Version
doi:10.1161/CIRCULATIONAHA.114.014522

Permanent link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:17295540

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA

Share Your Story
The Harvard community has made this article openly available. Please share how this access benefits you. Submit a story.

Accessibility
Cardiac troponin is the preferred marker of myocardial cell necrosis. Recently, highly sensitive assays have become available that allow the detection of very low concentrations of circulating cardiac troponin in healthy individuals. Increasing troponin concentrations, even those well within the normal reference interval, are positively associated with adverse cardiovascular outcome in primary prevention populations. These adverse outcomes include myocardial infarction (MI), congestive heart failure, and cardiovascular death. Assays for B-type natriuretic peptide (BNP) are widely used for diagnosis and risk stratification of patients presenting with suspected heart failure. BNP concentrations are also associated with adverse cardiovascular outcome in a variety of primary prevention and general populations.

Clinical Perspective on p 1860

Little is known about therapies that might improve cardiovascular outcome in stable patients with troponin or BNP concentrations that identify them as being at increased risk.
cardiovascular risk. In particular, whether statin therapy might mitigate this risk has not been well studied.

To address this question, we measured circulating cardiac troponin I with a novel high-sensitivity assay (hsTnI) and BNP in a contemporary cohort of patients without known cardiovascular disease who were randomly allocated to active statin therapy (rosuvastatin 20 mg daily) or placebo in the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. We sought to determine whether these markers of myocardial injury (hsTnI) and strain (BNP) were associated with adverse outcome in JUPITER and whether the effectiveness of statin therapy was modified by circulating hsTnI or BNP concentrations.

**Methods**

**Study Population**

JUPITER was a randomized, double-blind, placebo-controlled trial of rosuvastatin 20 mg/d conducted in 26 countries in men \(\geq 50\) years and women \(\geq 60\) years of age without a history of diabetes mellitus or cardiovascular disease and with a low-density lipoprotein (LDL) cholesterol \(<130\) mg/dL and a high-sensitivity C-reactive protein (hsCRP) \(\geq 2.0\) mg/L. The trial design and primary results have been described previously. In brief, rosuvastatin was associated with a 44% (hazard ratio [HR], 0.56; 95% confidence interval [CI], 0.46–0.69; \(P\) \(<0.00001\)) reduction in the trial primary end point, a composite of nonfatal MI, nonfatal stroke, hospitalization for unstable angina, arterial revascularization, or death resulting from cardiovascular causes. Of the 17,802 participants included in the parent trial, 12,956 had baseline samples available for analysis. Institutional review boards approved the JUPITER protocol at each site, and each participant gave written informed consent.

**Study End Points**

This study took as its primary end point the prespecified primary end point in the JUPITER trial: the occurrence of a first major vascular event, defined as the composite of nonfatal MI, nonfatal stroke, hospitalization for unstable angina, arterial revascularization, or death resulting from cardiovascular causes. All trial end points were

| Characteristic* | hsTnI Tertile 1 | hsTnI Tertile 2 | hsTnI Tertile 3 | \(P\) Value |
|----------------|----------------|----------------|----------------|-------------|
| Range in men, ng/L | \(<3.0\) | 3.0–<4.6 | \(\geq4.6\) | |
| Range in women, ng/L | \(<2.6\) | 2.6–<3.9 | \(\geq3.9\) | |
| Events/at risk, men, n | 34/2611 | 68/2887 | 119/2762 | |
| Events/at risk, women, n | 14/1475 | 21/1645 | 48/1576 | |
| Median (Q1–Q3) time to event, y | 1.83 (1.45–2.44) | 2.03 (1.56–2.48) | 2.02 (1.49–2.69) | <0.0001 |
| Age (Q1–Q3), y | 63 (58–68) | 66 (61–71) | 68 (63–74) | <0.0001 |
| Race or ethnic group, n (%) | | | | <0.0001 |
| White | 3217 (78.7) | 3839 (84.7) | 3538 (81.6) | |
| Black | 334 (8.2) | 243 (5.4) | 367 (8.5) | |
| Hispanic | 424 (10.4) | 361 (8.0) | 337 (7.7) | |
| Other | 111 (2.7) | 89 (2.0) | 94 (2.2) | |
| Hypertension, n (%) | 1829 (44.8) | 2473 (54.6) | 2906 (67.1) | <0.0001 |
| Systolic blood pressure, mm Hg | 130 (120–140) | 134 (125–146) | 139 (128–150) | <0.0001 |
| Diastolic blood pressure, mm Hg | 80 (74–85) | 80 (75–87) | 80 (75–87) | <0.0001 |
| Body mass index, kg/m² | 28.2 (25.1–31.9) | 28.4 (25.6–32.0) | 28.6 (25.6–32.1) | <0.0001 |
| Current smoking, n (%) | 767 (18.8) | 606 (13.4) | 597 (13.4) | <0.0001 |
| Family history of premature MI, n (%) | 541 (13.3) | 557 (12.3) | 553 (12.8) | 0.42 |
| Diabetes mellitus, n (%) | 13 (0.3) | 20 (0.4) | 31 (0.7) | 0.03 |
| Metabolic syndrome, n (%) | 1484 (36.6) | 1838 (40.9) | 1897 (44.2) | <0.0001 |
| Impaired fasting glucose, n (%) | 1228 (30.2) | 1490 (32.9) | 1496 (34.6) | <0.0001 |
| HbA₁c (Q1–Q3), % | 5.7 (5.4–5.9) | 5.7 (5.4–5.9) | 5.7 (5.5–5.9) | <0.0001 |
| Fasting glucose (Q1–Q3), mg/dL | 94 (88–101) | 95 (88–102) | 95 (88–103) | 0.0002 |
| Total cholesterol (Q1–Q3), mg/dL | 184 (167–199) | 187 (171–201) | 187 (172–201) | <0.0001 |
| LDL cholesterol (Q1–Q3), mg/dL | 106 (92–117) | 110 (97–120) | 110 (96–120) | <0.0001 |
| HDL cholesterol (Q1–Q3), mg/dL | 49 (41–60) | 49 (41–60) | 50 (41–61) | 0.88 |
| hsCRP (Q1–Q3), mg/L | 4.0 (2.7–6.6) | 4.0 (2.7–6.5) | 4.4 (3.0–7.5) | <0.0001 |
| Estimated GFR (Q1–Q3), mL/min | 75.8 (66.6–88.4) | 73.1 (64.9–82.2) | 71.0 (60.5–81.0) | <0.0001 |
| Framingham Risk Score (Q1–Q3) | 8 (5–12) | 10 (6–16) | 12 (8–20) | <0.0001 |
| Reynolds Risk Score (Q1–Q3) | 7 (4–12) | 10 (6–16) | 13 (7–21) | <0.0001 |
| Random allocation to rosuvastatin, n (%) | 2058 (50.4) | 2286 (50.4) | 2147 (49.5) | 0.62 |

GFR indicates glomerular filtration rate; HbA₁c, hemoglobin A₁c; HDL, high-density lipoprotein cholesterol; hsCRP, high-sensitivity C-reactive protein; hsTnI, high-sensitivity cardiac troponin I; LDL, low-density lipoprotein cholesterol; MI, myocardial infarction; and Q1–Q3, value at the 25th (Q1) and 75th (Q3) percentiles.

*Continuous variables are presented as median (Q1–Q3).
adjudicated by an independent committee of physicians blinded to treatment allocation. We also analyzed the association of baseline cardiac troponin and BNP concentrations with the individual components of the primary end point, as well as all-cause mortality, the composite of the primary end point plus all-cause mortality, and the occurrence of coronary heart disease, which is a composite of coronary revascularization, hospitalization for unstable angina, and all MI, including sudden death and nonfatal MI.

### Laboratory Analysis

All biomarkers were measured in EDTA plasma samples in the BiomarCaRE laboratory in Hamburg, Germany. hsTnI concentrations were determined by the ARCHITECT STAT hsTnI immunoassay (Abbott Diagnostics; ARCHITECT i2000SR). Because plasma volume was limited, we first measured hsTnI and then diluted the remaining plasma sample 1:1 before measurement of BNP. In total, adequate sample was available in 12,956 participants for hsTnI and 11,057 participants for BNP. The limit of detection for hsTnI is 1.9 ng/L, and 3.9 ng/L in women on the basis of the distribution of the biomarker within each sex. The limit of detection for BNP is 20 ng/L. Participants with BNP concentrations lower than this limit of detection (n=4990) were assigned a value of 19 ng/L for the determination of sex-specific tertiles and in analyses using natural logarithm (Ln)–transformed BNP concentrations as a linear variable. The intra-assay coefficient of variation for hsTnI was 4.32% to 6.72%, and the interassay coefficient of variation was 4.96% to 5.73%, and the interassay coefficient of variation was 4.96% to 5.73%, and the interassay coefficient of variation was 4.96% to 5.73%, and the interassay coefficient of variation was 4.96% to 5.73%, and the interassay coefficient of variation was 4.96% to 5.73%.

### Statistical Analysis

hsTnI concentrations were divided into increasing tertiles with the use of sex-specific cut points of 3.0 and 4.6 ng/L in men and 2.6 and 3.9 ng/L in women. Sex-specific tertile cut points for BNP were 20 and 28.6 ng/L in men and 20 and 44.4 ng/L in women on the basis of the distribution of the biomarker within each sex. The limit of detection for BNP is 20 ng/L. Participants with BNP concentrations lower than this limit of detection (n=4990) were assigned a value of 19 ng/L for the determination of sex-specific tertiles and in analyses using natural logarithm (Ln)–transformed BNP concentrations as a linear variable. The intra-assay coefficient of variation for BNP was 5.47% to 5.38%, and the interassay coefficient of variation was 4.32% to 6.72%.

The risk of a first major cardiovascular event* according to tertile of hsTnI or BNP measured at baseline is shown in Table 2.

### Table 2. Risk of a First Major Cardiovascular Event* According to Tertile of hsTnI or BNP Measured at Baseline

| Tertile 1† | Tertile 2 | Tertile 3 | P for Trend |
|-----------|-----------|-----------|-------------|
| HR (95% CI) |
| **Cardiac hsTnI**  |  |  |  |
| Events, n/person-y of observation | 48/8522 | 89/9851 | 167/9620 |
| Incidence rate per 100 person-years of observation | 0.56 | 0.90 | 1.74 | <0.0001 |
| Model 1 | 1.0 (Referent) | 1.41 (0.99–2.01) | 2.32 (1.66–3.23) | <0.0001 |
| Model 2 | 1.0 (Referent) | 1.40 (0.98–2.00) | 2.20 (1.57–3.09) | <0.0001 |
| Model 3 | 1.0 (Referent) | 1.40 (0.98–1.99) | 2.19 (1.56–3.06) | <0.0001 |
| Model 4 | 1.0 (Referent) | 1.30 (0.86–1.94) | 1.86 (1.25–2.76) | 0.001 |
| **BNP**  |  |  |  |
| Events, n/person-y of observation | 64/9866 | 42/4872 | 130/7514 |
| Incidence rate per 100 person-years of observation | 0.65 | 0.86 | 1.73 | <0.0001 |
| Model 1 | 1.0 (Referent) | 1.28 (0.86–1.90) | 1.99 (1.44–2.73) | <0.0001 |
| Model 2 | 1.0 (Referent) | 1.26 (0.85–1.88) | 1.95 (1.41–2.69) | <0.0001 |
| Model 3 | 1.0 (Referent) | 1.26 (0.85–1.88) | 1.94 (1.41–2.68) | <0.0001 |
| Model 4 | 1.0 (Referent) | 1.27 (0.85–1.89) | 1.93 (1.40–2.66) | <0.0001 |

Model 1: adjusted for age, race, sex, and study drug; model 2: adjusted for age, race, sex, study drug, body mass index, history of hypertension, current smoking, family history of myocardial infarction, total cholesterol, and high-density lipoprotein cholesterol; model 3: model 2 plus high-sensitivity C-reactive protein; and model 4: model 3 plus natural logarithm–transformed BNP (for hsTnI effect estimates) or natural logarithm–transformed hsTnI (for BNP effect estimates). BNP indicates B-type natriuretic peptide; CI, confidence interval; HR, hazard ratio; and hsTnI, high-sensitivity cardiac troponin I.

*A major cardiovascular event was defined as the occurrence of the Justification for the Use of Statins in Prevention: An Interventional Trial Evaluating Rosuvastatin (JUPITER) primary end point, a composite of nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina, arterial revascularization, or death resulting from cardiovascular causes.

†Sex-specific tertile cut points for hsTnI were 3.0 and 4.6 ng/L in men and 2.6 and 3.9 ng/L in women. Sex-specific tertile cut points for BNP were 20 and 28.6 ng/L in men and 20 and 44.4 ng/L in women.
tests for continuous variables and \( \chi^2 \) tests for categorical variables. The risk and 95% CIs of the JUPITER primary end point, the individual components of the primary end point, all-cause mortality, the composite of any coronary heart disease event, and the composite of the primary end point or all-cause mortality according to increasing tertiles of hsTnI or BNP were calculated with Cox proportional hazards models adjusted for cardiovascular risk factors and study drug allocation. Four models were constructed with adjustments for the following covariates: model 1: age, race, sex, and study drug allocation; model 2: model 1 covariates plus body mass index, history of hypertension, current smoking, family history of MI, and total and high-density lipoprotein cholesterol; model 3: model 2 covariates plus hsCRP; and model 4: model 3 covariates plus Ln-BNP (for hsTnI effect estimates) or Ln-hsTnI (for BNP effect estimates). No violation of the proportional hazards assumption across tertiles of hsTnI \((P=0.36)\) or BNP \((P=0.91)\) was detected. The association per 1-SD of Ln-hsTnI and Ln-BNP was also calculated. Possible heterogeneity in the effects of statin therapy across biomarker tertiles was evaluated in a proportional hazards model that included tertile indicators, an indicator of rosuvastatin assignment, and an interaction term combining statin assignment and biomarker tertile. Incidence rates of the primary end point were calculated for patients randomly allocated to active or placebo rosuvastatin. Absolute risk reductions were defined as the incidence rate differences and 95% CIs between the active and placebo arms. Incidence rate differences (95% CI) were used to estimate the 5-year numbers needed to treat (NNTs) according to tertile of baseline hsTnI or BNP and rosuvastatin assignment.

**Results**

In total, 12956 JUPITER participants had baseline samples available that were successfully analyzed for cardiac TnI, and 11057 had samples successfully analyzed for BNP. Compared with the JUPITER participants for whom no blood sample was available, the cohort with blood samples available for hsTnI testing was more likely to be male and white, among other differences (Table I in the online-only Data Supplement). The median follow-up time in this cohort was 2.0 years (quartile 1–3 [Q1–Q3], 1.5–2.5 years).

The median hsTnI concentration was 3.4 ng/L (Q1–Q3, 2.6–5.0 ng/L) and was higher in men (3.6 ng/L; Q1–Q3, 2.7–5.3 ng/L) than in women [3.1 ng/L; Q1–Q3, 2.3–4.5 ng/L; \( P<0.0001 \)]. In total, 11905 of 12956 participants (91.9%) had hsTnI concentrations above the manufacturer’s limit of detection of 1.9 ng/L, and a higher proportion of men (7744 of 8260, 93.8%) than women (4161 of 4696, 88.6%) had values above this threshold \((P<0.0001)\). The proportion of men with a value at or above the proposed upper reference limit of 36 ng/L was 2.9% (235 of 8260) compared with 4.1% (193 of 4696) of women above the proposed upper reference limit of 15 ng/L. The median BNP concentration was 22.3 ng/L (Q1–Q3, 19.0–42.7 ng/L) and was lower in men (19.0 ng/L; Q1–Q3, 19.0–35.3 ng/L) than in women (29.2 ng/L; Q1–Q3, 19.0–53.4 ng/L; \( P<0.0001 \)).

Baseline characteristics stratified by baseline tertile of hsTnI are presented in Table I, and baseline characteristics stratified by baseline tertile of BNP are presented in Table II in the online-only Data Supplement. Age, systolic and diastolic blood pressures, the prevalence of hypertension, total cholesterol, LDL cholesterol, the Framingham Risk Scores, and the Reynolds Risk Score were all positively correlated with baseline hsTnI and BNP. The metabolic syndrome, impaired fasting glucose, fasting glucose, and hsCRP were positively correlated with hsTnI and inversely correlated with BNP. Both

---

**Figure 1.** Cumulative incidence of a first major cardiovascular event according to baseline tertile of high-sensitivity cardiac troponin I (hsTnI tertile; A) or B-type natriuretic peptide (BNP tertile; B). A first major cardiovascular event is defined as the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) primary end point (nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina, arterial revascularization, or death resulting from cardiovascular causes). The sex-specific tertile cut points for hsTnI were 3.0 and 4.6 ng/L in men and 2.6 and 3.9 ng/L in women. The sex-specific tertile cut points for BNP were 20 and 28.6 ng/L in men and 20 and 44.4 ng/L in women. For the Kaplan–Meier analysis and log-rank \( P \) values presented here, follow-up was limited to 2.5 years, when 25% and 20% of patients remained in the hsTnI and BNP analyses, respectively.
biomarkers were inversely correlated with estimated glomerular filtration rate. In sex-stratified analyses of a variety of baseline biomarkers, hsTnI and BNP were correlated with one another ($p=0.30$ in men and 0.25 in women; Tables III and IV in the online-only Data Supplement).

The unadjusted incidence of the composite primary end point increased with increasing hsTnI category, from 0.56 per 100 person-years in the first tertile to 1.74 events per 100 person-years in the third tertile ($P<0.0001$; Table 2 and Figure 1A). Participants with an hsTnI lower than the limit of detection (1.9 ng/L) had an incidence of the primary end point of 0.14 per 100 person-years. After adjustment for age, race, sex, study drug assignment, cardiovascular risk factors, and hsCRP, the highest tertile of hsTnI was at more than double the risk of the composite cardiovascular outcome (model 3 HR, 2.19; 95% CI, 1.56–3.06; $P$ for trend<0.0001). Adjusting for BNP led to a modest attenuation of this estimate (HR, 1.86; 95% CI, 1.25–2.76; $P$ for trend=0.001). As a sensitivity analysis, we excluded those with hsTnI concentrations in the abnormal range, and the adjusted risk of the primary end point for those in the highest compared with the lowest tertile was essentially unchanged (model 3 HR, 2.25; 95% CI, 1.25–3.17; $P$ for trend <0.0001). When analyzed as a linear variable, hsTnI demonstrated an independent association with the primary outcome (model 3 HR per 1-SD Ln-hsTnI, 1.38; 95% CI, 1.23–1.53; $P<0.0001$)

We observed no significant difference in the relationship between hsTnI or BNP and the JUPITER primary end point when analyses were stratified by random allocation to rosuvastatin or placebo (Figure I in the online-only Data Supplement; $P$ for interaction=0.53 and 0.20, respectively).

The association of hsTnI and BNP with the JUPITER primary end point was consistent across a number of key risk subgroups, including age ≥70 or <70 years, men and women,

![Figure 2](image-url)

**Figure 2.** Adjusted hazard ratios and 95% confidence intervals of a first major cardiovascular event for the highest vs lowest tertile of high-sensitivity cardiac troponin I (hsTnI) stratified by a number of key risk subgroups. Risk estimates are adjusted for age, sex, drug, race, hypertension, smoking, body mass index (BMI), total cholesterol, high-density lipoprotein (HDL) cholesterol, family history of coronary heart disease, and high-sensitivity C-reactive protein (hsCRP) at baseline. LDL indicates low-density lipoprotein. *Incidence rates are per 100 person-years of observation.
white and nonwhite participants, and those with favorable and unfavorable lipid or metabolic traits (Figure 2). Similarly consistent associations were observed for BNP (Figure 3).

The independent associations of hsTnI with each of the individual components of the primary end point, as well as death and coronary heart disease, are displayed in Figure 4. Participants with hsTnI values in the top tertile were at increased risk of cardiovascular mortality (HR, 2.45; 95% CI, 0.97–6.18; \( P \) for trend=0.03), nonfatal MI (HR, 3.08; 95% CI, 1.52–6.26; \( P \) for trend=0.0008), nonfatal stroke (HR, 2.9; 95% CI, 1.58–5.38; \( P \) for trend=0.0003), and hospitalization for unstable angina (HR, 2.77; 95% CI, 1.49–5.18; \( P \) for trend=0.0008).

**Figure 3.** Adjusted hazard ratios and 95% confidence intervals of a first major cardiovascular event for the highest vs lowest tertile of B-type natriuretic peptide (BNP) stratified by a number of key risk subgroups. Risk estimates for are adjusted for age, sex, drug, race, hypertension, smoking, body mass index (BMI), total cholesterol, high-density lipoprotein (HDL) cholesterol, family history of coronary heart disease, and high-sensitivity C-reactive protein (hsCRP) at baseline. LDL indicates low-density lipoprotein. *Incidence rates are per 100 person-years. Total N=12956.

**Figure 4.** Adjusted hazard ratios and 95% confidence intervals for the highest vs lowest tertile of high-sensitivity cardiac troponin I (hsTnI) for the individual components of the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) composite primary end point, as well as all-cause death and coronary heart disease, and the composite of the primary end point or all-cause death. Risk estimates are adjusted for age, sex, drug, race, hypertension, smoking, body mass index, total cholesterol, high-density lipoprotein cholesterol, family history of coronary heart disease, and high-sensitivity C-reactive protein at baseline. *Incidence rates are per 100 person-years. Total N=12956.
1.84; 95% CI, 0.93–3.64; \(P\) for trend=0.04), and hospitalization for unstable angina (HR, 3.36; 95% CI, 1.21–9.30; \(P\) for trend=0.01). We also observed a statistically robust relationship between hsTnI and all-cause mortality (HR, 2.61; 95% CI, 1.81–3.78; \(P\) for trend <0.0001) and between the composite of the primary end point plus all-cause mortality (HR, 2.42; 95% CI, 1.86–3.15; \(P\) for trend <0.0001). BNP demonstrated independent associations with MI, stroke, arterial revascularization, all-cause mortality, coronary heart disease, and the composite of the primary end point plus all-cause mortality (Figure 5).

Rosuvastatin was equally effective in preventing the occurrence of the primary end point across different baseline concentrations of either hsTnI or BNP (Table 3 and Figure II in the online-only Data Supplement). For example, rosuvastatin therapy was associated with a 42% reduction in the adjusted relative risk of the primary end point in the first tertile of hsTnI and a 50% reduction in the third tertile (Table 3).

### Table 3. Risk of the JUPITER Primary End Point for Rosuvastatin Versus Placebo Stratified by Tertile of Baseline hsTnI, Tertile of BNP, or Framingham Risk Score

| Tertile of Risk Marker at Baseline | Rosuvastatin | Placebo |
|----------------------------------|-------------|---------|
|                                  | Events/At Risk, n | Incidence Rate | Events/At Risk, n | Incidence Rate | Absolute Risk Reduction (95% CI) | HR (95% CI) | \(P\) for Interaction |
| hsTnI                            |              |          |              |          |                          |          |                          |
| 1                                | 18/2058      | 0.42     | 30/2028      | 0.71     | 0.30 (-0.02 to 0.62)     | 0.58 (0.32 to 1.04) | 0.53 |
| 2                                | 34/2286      | 0.68     | 55/2246      | 1.13     | 0.44 (0.07 to 0.82)      | 0.60 (0.39 to 0.93) |      |
| 3                                | 56/2147      | 1.17     | 111/2191     | 2.29     | 1.12 (0.59 to 1.64)      | 0.50 (0.36 to 0.69) |      |
| BNP                              |              |          |              |          |                          |          |                          |
| 1                                | 19/2510      | 0.38     | 45/2475      | 0.91     | 0.53 (0.21 to 0.85)      | 0.42 (0.25 to 0.72) | 0.20 |
| 2                                | 15/1195      | 0.61     | 27/1204      | 1.12     | 0.51 (-0.02 to 1.03)     | 0.56 (0.30 to 1.05) |      |
| 3                                | 51/1829      | 1.36     | 79/1844      | 2.10     | 0.74 (0.15 to 1.33)      | 0.62 (0.43 to 0.88) |      |
| Framingham Risk Score, %         |              |          |              |          |                          |          |                          |
| ≤5                               | 9/1494       | 0.30     | 14/1420      | 0.49     | 0.20 (-0.13 to 0.52)     | 0.61 (0.26 to 1.42) | 0.40 |
| >5–<10                           | 24/1840      | 0.60     | 38/1842      | 0.94     | 0.34 (-0.04 to 0.72)     | 0.67 (0.40 to 1.12) |      |
| >10                              | 74/3148      | 1.05     | 144/3198     | 2.05     | 1.00 (0.58 to 1.41)      | 0.50 (0.37 to 0.66) |      |

A test for interaction between each of the risk markers and allocation to rosuvastatin or placebo revealed no evidence of interaction. BNP indicates B-type natriuretic peptide; CI, confidence interval; HR, hazard ratio; hsTnI, high-sensitivity cardiac troponin I; JUPITER, Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin.

*Sex-specific tertile cut points for hsTnI were 3.0 and 4.6 ng/L in men and 2.6 and 3.9 ng/L in women. Sex-specific tertile cut points for BNP were 20 and 28.6 ng/L in men and 20 and 44.4 ng/L in women.

†Incidence rates are per 100 person-years of observation.

‡Absolute risk reduction is per 100 person-years of observation and is defined as the incidence rate difference (95% CI) between the active and placebo arms.

§Adjusted for age, sex, race, study drug, body mass index, history of hypertension, current smoking, family history of myocardial infarction, total cholesterol, high-density lipoprotein cholesterol, and high-sensitivity C-reactive protein.
interaction=0.53). These results are consistent with the overall effect of rosuvastatin on the primary end point in this subcohort of JUPITER (HR, 0.55; 95% CI, 0.43–0.69; Figure II in the online-only Data Supplement) and in the trial as a whole.13

The absolute risk of the JUPITER primary end point appeared to increase across categories of hsTnI (Table 3). The absolute risk reduction, calculated as the difference in the incidence rates of the primary end point between the active and placebo arms, was 0.30 (95% CI, −0.02 to 0.62) in the lowest tertile of hsTnI, yielding an estimated 5-year NNT of 67. In the highest tertile of hsTnI, the absolute risk reduction of the primary end point between active and placebo was 1.12 (95% CI, 0.59–1.64), for an estimated 5-year NNT of 18. These results are similar to those observed when the cohort is stratified by Framingham Risk Score (Table 3), which had an NNT of 103 for the lowest risk scores (≤5%) and 20 for the highest (>10%). BNP did not appear to have as strong a relationship with absolute risk, with absolute risk reductions ranging from 0.53 (95% CI, 0.21–0.85) for the lowest tertile to 0.74 (95% CI, 0.15–1.33) in the highest tertile (Table 3). NNTs for BNP ranged from 38 for the lowest tertile to 27 for the highest tertile.

Discussion

In this prospective examination of 12 956 men and women with normal cholesterol levels and no prior cardiovascular disease, we demonstrated a statistically robust association between baseline concentrations of circulating cardiac TnI, as measured by a high-sensitivity assay, and the occurrence of major vascular events and death. This association was consistent across a variety of subgroups and was observed for a number of clinically important end points, including all-cause mortality, cardiovascular mortality, MI, stroke, and hospitalization for unstable angina. Similarly robust associations were observed for BNP. Rosuvastatin offered similar relative reductions in the risk of major vascular events regardless of baseline hsTnI or BNP concentrations. In the highest category of baseline hsTnI, rosuvastatin therapy was associated with the most substantial reduction in the absolute risk of cardiovascular events and therefore the lowest NNTs.

We believe these results have clinical implications for a number of reasons. First, the men and women enrolled in JUPITER had no prior evidence of cardiovascular disease or diabetes mellitus and were required to have an LDL cholesterol <130 mg/dL to be eligible. Nonetheless, nearly 94% of men and 89% of women had detectable concentrations of circulating cardiac troponin. These results are comparable to those obtained from a population based study in a European cohort14 and are consistent with reports from clinical trials of patients with atrial fibrillation and stable coronary artery disease.17,18 hsTnI concentrations in JUPITER participants are lower than those in populations with prevalent cardiovascular disease. In primary prevention or general populations, the prevalence of circulating cardiac troponin T ranges from 30% among healthy middle-aged women15 to ≈70% among men and women with a mean age >70 years.6

Most of the men and women in JUPITER had circulating hsTnI concentrations that were lower than thresholds that have been proposed as a diagnostic cutoff for MI in the appropriate clinical context.5,15 In this contemporary primary prevention population, 2.9% of men and 4.1% of women had TnI concentrations above proposed sex-specific upper reference limits.5,15,16 Nonetheless, we observed a clear gradient of risk among those with hsTnI concentrations below these thresholds such that the men and women with a hsTnI in the top tertile (≥4.6 ng/L in men and ≥3.9 ng/L in women) were at 2.2-times higher risk of a first major vascular event, including cardiovascular mortality, with an absolute rate of 2.3 events per 100 person-years of observation in the placebo arm. These observations are consistent with those in patients with existing coronary artery disease and in those with atrial fibrillation, among whom hsTnI was correlated with the risk of stroke/systemic embolism, cardiac mortality, and major bleeding.17,18

Rosuvastatin was equally effective in reducing the relative risk of major vascular events across categories of hsTnI and BNP. These results are similar to those seen for hsCRP in a previously published analysis of all 17 802 JUPITER participants.19 In this study, hsTnI appeared to be more closely related to the absolute risk of the primary end point than did BNP. The absolute benefit of rosuvastatin increased with increasing hsTnI level, and the calculated NNT for 5 years to prevent 1 primary end point in the highest tertile of hsTnI (NNT=18) compares favorably with the estimated NNT for a Framingham Risk Score >10% (NNT=20) or the highest tertile of BNP (NNT=27). When the results reported here are viewed in the context of previously published analyses of the NNT in JUPITER, hsTnI appears as useful as other accepted markers of high absolute risk such as advanced age, a history of hypertension, or low high-density lipoprotein cholesterol in helping to identify a group of patients with an NNT <20.20 This number compares favorably with other interventions in primary prevention populations such β-blockers or diuretics for hypertension or aspirin.20–23 The absolute risk reductions observed with statin therapy in secondary prevention populations, however, are more substantial.24 For example, the NNT for only 1 year in the Cholesterol and Recurrent Events (CARE) trial, a secondary prevention trial of pravastatin 40 mg in patients with prior MI and LDL between 115 and 174 ng/L, was 33 (95% CI, 20–99).24,25

We were unable to determine whether rosuvastatin therapy altered circulating hsTnI or BNP concentrations because of a lack of follow-up blood samples. However, secondary analyses of the Controlled Rosuvastatin Multinational Trial in HF (CORONA) study reported no difference in high-sensitivity cardiac troponin T concentrations after 3 months of rosuvastatin 10 mg/d.26

We observed similarly robust associations between baseline BNP concentrations and the occurrence of major vascular events. Both cardiac troponin and BNP appear to provide independent information on future cardiovascular risk in JUPITER, observations that are consistent with those from other primary prevention cohorts that have measured both cardiac troponin and natriuretic peptides.3,4,27

The cause for the ongoing troponin release in otherwise stable individuals is incompletely understood. Age, male sex, black race, renal function, diabetes mellitus, hypertension, left ventricular hypertrophy, and a history of heart failure have all been reported as determinants of circulating cardiac troponin
T concentrations,2-4,6 and data from a secondary prevention cohort suggest that the determinants of cardiac troponin T and TnI are similar.18 In the Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) data, the determinants of hsTnI concentration were similar to those reported for cardiac troponin T but also included peripheral or persistent atrial fibrillation.17 The mechanisms of troponin release in patients enrolled in JUPITER and other stable patients are likely to represent a combination of a number of different pathophysiological processes, including myocardial cell necrosis, apoptosis, hemodynamic stress, and metabolic abnormalities. Some have proposed increased rates of myocardial cell turnover or changes in cell wall permeability.28,29

Strengths of our study include the relatively large sample size of individuals without known pre-existing vascular disease, its prospective nature, the number of women, and the random allocation of statin therapy in the parent trial. These strengths, plus the relatively large number of vascular events and deaths, allow the estimation of the association of each hsTnI and BNP with adverse outcome and the assessment of whether statin therapy alters that relationship. Limitations include the fact that participants were followed up for a median of 2 years (maximum, 5 years), so the longer-term implications of hsTnI and BNP concentrations cannot be determined in this cohort. In addition, although we had adequate plasma for the hsTnI assay, the lack of adequate plasma for BNP means that many participants have no BNP value or have a value that is below the limit of detection in a diluted sample.

Conclusions

In this population of patients with normal LDL cholesterol concentrations and no known pre-existing cardiovascular disease, cardiac TnI can be detected in 92% and exceeds sex-specific reference limits in 3% of participants. We observed a statistically robust relationship between baseline measures of myocardial injury (cardiac TnI) and myocardial strain (BNP) and the risk of a vascular events, as well as death, in the entire cohort and in a variety of high- and low-risk patient subgroups. The benefits of rosuvastatin compared with placebo were substantial and consistent regardless of baseline hsTnI or BNP concentrations. Cardiac TnI appeared to be able to identify individuals at particularly high absolute risk of vascular events, a group among whom rosuvastatin offered a substantial reduction in the absolute risk of these clinically important events.

Sources of Funding

JUPITER was an investigator-initiated study supported by AstraZeneca. This work has been supported by the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement No. HEALTH-F2-2011-278913 (BiomarCaRE). Abbott Diagnostics provided reagents for TnI and BNP.

Disclosures

Dr Everett reports research support from Roche Diagnostics and Novartis Pharmaceuticals and serves as consultant to SOCAR research. Dr Glynn reports research support from Novartis and the National Institutes of Health. Dr Ridker has received investigator-initiated research grants from the National Institutes of Health, the American Heart Association, the Leducq Foundation, the Reynolds Foundation, AstraZeneca, Novartis, Amgen, and Pfizer; has served as a consultant to Pfizer, ISIS, Amgen, Vascular Biogenics, and BostonHeart; and is listed as the coinventor of patents held by the Brigham and Women’s Hospital that relate to the use of inflammatory biomarkers in cardiovascular disease. Dr Blankenberg has received honoraria from Abbott Diagnostics, SIEMENS, Thermo Fisher, and Roche Diagnostics and is a consultant for Thermo Fisher. The sponsor played no role in the design or conduct of this study; in the management, analysis, or interpretation of the data; or in the preparation, review, or approval of the manuscript or in the decision to submit the manuscript for publication. Dr Zeller reports no conflicts.

References

1. Thygensen K, Alpert JS, White HD; Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. *Eur Heart J*. 2007;28:2525–2538. doi: 10.1093/eurheartj/ehm355.
2. Everett BM, Cook NR, Magnarelli MC, Bobadilla M, Kim E, Rifai N, Ridker PM, Pradhan AD. Sensitive cardiac troponin T assay and the risk of incident cardiovascular disease in women with and without diabetes mellitus: the Women’s Health Study. *Circulation*. 2011;123:2811–2818. doi: 10.1161/CIRCULATIONAHA.110.009092.
3. de Lemos JA, Dezner MH, Omland T, Ayers CR, Khera A, Rohatgi A, Hashim I, Berry JD, Das SR, Morrow DA, McGuire DK. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. *JAMA*. 2010;304:2503–2512. doi: 10.1001/jama.2010.1768.
4. defilippi CR, de Lemos JA, Christenson RH, Gottoliender JS, Kop WJ, Zhan M, Seliger SL. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. *JAMA*. 2010;304:2494–2502. doi: 10.1001/jama.2010.1708.
5. Zeller T, Tunstall-Pedhoe H, Saarela O, Ojeda F, Schnabel RB, Tuovinen T, Woodward M, Struthers A, Hughes M, Kie F, Salomaa V, Kuulasmaa K, Blankenberg S; MORGAM Investigators. High population prevalence of cardiac troponin I measured by a high-sensitivity assay and cardiovascular risk estimation: the MORGAM Biomarker Project Scottish Cohort. *Eur Heart J*. 2014;35:271–281. doi: 10.1093/eurheartj/ehq406.
6. Saunders JT, Nambi V, de Lemos JA, Chambless LE, Virani SS, Boerwinkle E, Hoogeveen RC, Liu X, Aster BC, Mosley TH, Folsom AR, Heiss G, Groesh J, Ballantyne CM. Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study. *Circulation*. 2011;123:1367–1376. doi: 10.1161/CIRCULATIONAHA.110.005264.
7. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duce P, Omland T, Storrow AB, Abraham WT, Wu AH, Plotz P, Steg PG, Westheim A, Knudsen CW, Perez A, Kazanegra R, Herrmann HC, McCullough PA; Breathing Not Properly Multinational Study Investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. *N Engl J Med*. 2002;347:161–167. doi: 10.1056/NEJMoa02233.
8. Thygensen K, Maer J, Mueller C, Huber K, Weber M, Plebani M, Hasin Y, Biasucci LM, Giannitsis E, Lindahl B, Koenig W, Tiburo M, Collinson P, Katus H, Galvani M, Venge P, Alpert JS, Haman C, Jaffe AS; Study Group on Biomarkers in Cardiac Care: a position statement from the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care. Recommendations for the use of natriuretic peptides in acute cardiac care: a position statement from the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care. *Eur Heart J*. 2012;33:2001–2006. doi: 10.1093/eurheartj/ehq509.
9. Wuerter TJ, Larson MG, Levy D, Benjamin EJ, Levy FP, Omland T, Wolf PA, Vasan RS. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. *N Engl J Med*. 2004;350:655–663. doi: 10.1056/NEJMoa031994.
10. Di Angelantonio E, Chowdhury R, Sarwar N, Ray K, Gobin R, Saleheen D, Thompson A, Gudmundsson V, Sattar N, Danesh J. B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies. *Circulation*. 2009;120:2177–2187. doi: 10.1161/CIRCULATIONAHA.109.884866.
11. Blankenberg S, Zeller T, Saarela O, Havalinna AS, Kee F, Tunstall-Pedoe H, Kaualnresa K, Yarnell J, Schnabel RB, Wild PS, Münzel TF, Lackner KJ, Tietl L, Evans A, Salomaa V; MORGAM Project. Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MÓNICA, Risk, Genetics, Archiving, And Monograph (MORGAM) biomarker project. *Circulation*. 2010;121:2388–2397. doi: 10.1161/CIRCULATIONAHA.109.901413.

Circulating concentrations of cardiac troponin and B-type natriuretic peptide (BNP) as markers of myocardial necrosis and strain, respectively, have shown strong, consistent associations with adverse cardiovascular outcomes, including myocardial infarction, stroke, and cardiovascular death. Little is known about therapies that might improve outcomes for patients with cardiac troponin or BNP concentrations that place them at increased cardiovascular risk. In this study, we sought to determine whether statin therapy might be particularly effective in patients with higher concentrations of either cardiac biomarker.

We measured cardiac troponin I with a novel, high-sensitivity assay (hsTnI) and BNP in 12,956 men and women enrolled in the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. Rosuvastatin use in participants with higher hsTnI concentrations led to a substantial reduction in the absolute risk of a first major vascular event for all participants. Because hsTnI appeared to identify individuals at high absolute risk of vascular events, rosvastatin use in participants with higher hsTnI concentrations led to a substantial reduction in the absolute risk of these clinically important events.

**CLINICAL PERSPECTIVE**

Circulating concentrations of cardiac troponin and B-type natriuretic peptide (BNP) as markers of myocardial necrosis and strain, respectively, have shown strong, consistent associations with adverse cardiovascular outcomes, including myocardial infarction, stroke, and cardiovascular death. Little is known about therapies that might improve outcomes for patients with cardiac troponin or BNP concentrations that place them at increased cardiovascular risk. In this study, we sought to determine whether statin therapy might be particularly effective in patients with higher concentrations of either cardiac biomarker.

We measured cardiac troponin I with a novel, high-sensitivity assay (hsTnI) and BNP in 12,956 men and women enrolled in the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. Rosuvastatin use in participants with higher hsTnI concentrations led to a substantial reduction in the absolute risk of a first major vascular event for all participants. Because hsTnI appeared to identify individuals at high absolute risk of vascular events, rosvastatin use in participants with higher hsTnI concentrations led to a substantial reduction in the absolute risk of these clinically important events.